Cancer research representativeness is the degree to which study participants, biospecimens, and research data reflect the people who may develop or receive care for cancer. Gaps are often hidden in plain sight: a large trial can still provide limited evidence for groups who were under-enrolled, excluded, or not described in published results. The National Cancer Institute reports that Black people make up about 13% of the U.S. population but only about 2% of participants in cancer clinical trials. Such imbalances can limit how confidently researchers apply findings across populations, especially when treatment effects, access to care, or cancer risks differ. Understanding who is missing means examining trial enrollment, demographic reporting, genomic datasets, and the practical barriers that shape participation—then improving recruitment and accountability.
Cancer research representativeness: definition and scope
Representativeness in cancer research describes how well the people and materials studied reflect the population to which a finding is intended to apply. The National Academies of Sciences, Engineering, and Medicine has emphasized that diversity in clinical research is essential to producing evidence relevant to the populations affected by disease. Representativeness is not simply a requirement to match national census percentages: appropriate comparison depends on the cancer, intervention, study question, and population likely to use the findings.
The concept includes several related forms: representation in clinical trials, representation in observational studies and tissue collections, and representation in genomic or other research datasets. Each can fail differently. A trial may enroll a diverse group but publish too little subgroup information to assess outcomes; a genomic database may contain many samples but draw disproportionately from people of European ancestry. These distinctions help explain why a headline enrollment number alone cannot establish that evidence is broadly applicable.
Enrollment representation in clinical trials
Clinical-trial representation concerns who is invited, screened, enrolled, retained, and included in analyses. The U.S. Food and Drug Administration’s 2020 guidance on enhancing diversity in clinical trials recommends planning recruitment around the disease population and addressing barriers that affect participation. In cancer research, those barriers may include travel to specialist centers, time away from work, caregiving responsibilities, insurance or cost concerns, language access, and restrictive eligibility criteria.
The National Cancer Institute has highlighted persistent underrepresentation of racial and ethnic minority groups in cancer trials. The approximate comparison often cited—Black people at about 13% of the U.S. population and about 2% of cancer-trial participants—illustrates the scale of one gap, although the figures vary by cancer type, trial, and reporting period. A fair assessment should also examine age, sex, disability, geography, socioeconomic circumstances, and other characteristics relevant to the research question.
Representation in biospecimens and genomic datasets
Biospecimen representation concerns whose tumor tissue, blood, and other biological samples are available for study. Genomic representation concerns whose genetic variation and molecular profiles inform research tools and treatment discoveries. These categories are connected but not interchangeable: a dataset can include samples from many patients while still lacking adequate demographic, clinical, or ancestry information to support meaningful comparisons.
A landmark 2019 analysis by researchers including Alicia R. Martin and colleagues, published in Cell, found that people of European ancestry accounted for 78% of participants in genome-wide association studies, while people of African ancestry accounted for 2%. Although the analysis covered human genetics broadly rather than cancer alone, the imbalance matters to cancer genomics because risk models and molecular findings may be less reliable when applied to populations underrepresented in discovery datasets. The National Cancer Institute’s Cancer Genome Atlas and other large programs have expanded tumor profiling, but sample diversity and consistent reporting remain important considerations when translating discoveries into practice.
Cancer research gaps: causes and consequences
Once representation is measured across trials and datasets, the next question is why gaps persist. Underrepresentation is not explained by a lack of interest from communities alone. Research design, recruitment systems, institutional trust, financial and logistical burdens, and eligibility rules can all shape who has a realistic opportunity to participate. The resulting evidence gaps can affect both scientific conclusions and the fairness of care.
Structural and practical barriers to participation
Structural barriers are conditions that make access to research uneven, including the concentration of trials at major academic centers, limited transportation, inflexible visit schedules, and inadequate language services. A 2021 review in the Journal of Clinical Oncology described how trial access and enrollment are influenced by interacting patient, clinician, study, and health-system factors. Eligibility rules can also exclude people with common coexisting conditions or prior treatments, narrowing the participant pool beyond what is scientifically necessary.
These barriers can compound. For example, a person who lives far from a trial site and cannot take paid leave may be effectively excluded even if the protocol technically permits enrollment. Decentralized visits, travel support, translated materials, community-based research partnerships, and broader eligibility criteria can reduce some obstacles when they are appropriate to the study and supported by safeguards.
Trust, consent, and community partnership
Trust affects whether people consider research participation and whether they are willing to contribute samples or data. Historical abuses, present-day discrimination, poor communication, and a lack of visible benefit can weaken confidence in research institutions. Trust-building therefore requires more than recruitment messaging: it depends on clear consent, respectful engagement, transparent communication about results and data use, and meaningful partnerships with communities before a study begins.
The National Academies has argued that engagement should be sustained and reciprocal, rather than limited to asking communities to enroll after a protocol is finalized. Community advisers can help researchers identify inconvenient procedures, culturally or linguistically unclear materials, and concerns about privacy. These approaches do not guarantee enrollment, but they can make participation more accessible and research more responsive to the people it aims to serve.
What underrepresentation can mean for evidence and care
When groups are missing or too few for meaningful analysis, researchers may be unable to estimate whether a treatment’s benefits, side effects, or practical burdens differ across populations. The problem is not that every study must be powered to detect every subgroup effect; rather, evidence should be interpreted with appropriate limits, and research programs should fill important gaps over time. The FDA notes that diverse enrollment can help characterize treatment effects and support understanding of how therapies perform in the populations likely to receive them.
In genomics, uneven ancestry representation can reduce the accuracy of risk prediction and make discoveries less transferable. In clinical research, missing demographic data can hide who was not reached or whether enrollment reflects the disease burden. In both cases, an apparent universal finding may rest on evidence drawn from a narrower population than its use implies.
Measuring and closing cancer research representativeness gaps
Closing gaps requires measurement that is transparent, specific, and connected to action. Researchers and sponsors can compare enrollment with the population affected by the cancer under study, report screening and retention as well as final enrollment, and explain exclusions. Regulators, funders, journals, institutions, and community partners each have a role in making representation a routine part of research quality rather than an afterthought.
Report who participated—and who did not
A useful representation report describes participant characteristics, recruitment locations, eligibility criteria, and missing demographic information. It distinguishes people approached, screened, eligible, enrolled, and retained, because disparities can arise at any step. The FDA’s 2020 guidance recommends a Race and Ethnicity Diversity Plan for many clinical trials, encouraging sponsors to set enrollment goals and explain strategies for achieving them.
Researchers should avoid treating race as a simple biological proxy. Race and ethnicity are social and historical categories that can capture exposure to structural conditions, while genetic ancestry is a different concept. Clear definitions and careful interpretation reduce the risk of turning demographic categories into unsupported biological explanations.
Design studies around access and inclusion
Inclusive design begins before recruitment. Researchers can consult patients and community organizations while developing protocols, assess whether eligibility restrictions are scientifically necessary, offer materials in relevant languages, and select sites that reach populations affected by the disease. Practical supports—such as transportation assistance, flexible scheduling, childcare support where feasible, and remote follow-up—can address burdens that otherwise make participation unrealistic.
A real-world example is the growing use of community oncology practices and broader trial networks to bring studies closer to patients who may not live near major research hospitals. Such approaches can improve geographic access, but they require adequate staffing, training, infrastructure, and consistent data quality. Expanding sites without those supports may shift burdens rather than remove them.
Improve data stewardship and accountability
Data stewardship means collecting, protecting, documenting, and sharing research data responsibly. High-quality datasets should include useful demographic and clinical context, explain missingness, and describe how samples and information may be reused. Governance should also address privacy and community concerns, especially for populations that have faced misuse or stigmatizing interpretations of research data.
Accountability can include public reporting of enrollment goals and outcomes, funder requirements, ongoing review of recruitment progress, and publication of limitations. Researchers should not claim broad generalizability merely because a study is large. A chart comparing trial enrollment with the relevant cancer population—alongside screening, retention, and missing-data rates—can make representativeness gaps visible to readers and decision-makers.
Conclusion: make representation part of cancer research quality
Cancer research representativeness spans clinical-trial enrollment, biospecimens, and genomic datasets. Evidence such as the National Cancer Institute’s reported gap between Black people’s share of the U.S. population and their share of cancer-trial participation, together with broader genomic studies showing ancestry imbalances, demonstrates why missing representation can be easy to overlook yet consequential. Structural access barriers, trust, study design, and weak reporting all contribute, while better measurement, community partnership, inclusive protocols, and responsible data stewardship offer practical routes forward.
Patients, researchers, institutions, sponsors, and funders can help by asking who is represented, who is missing, and whether the evidence supports the populations expected to benefit. For further reading, consult the FDA’s guidance on clinical-trial diversity, National Cancer Institute resources on cancer clinical trials, and National Academies reports on inclusive research. Representation is not a substitute for rigorous science; it is part of making rigorous science relevant, trustworthy, and useful.
Sources: National Cancer Institute, “Cancer Clinical Trials and Racial and Ethnic Minorities,” https://www.cancer.gov/about-cancer/treatment/clinical-trials/participating/racial-ethnic-minorities; U.S. Food and Drug Administration, “Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry,” 2020, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial; Martin, A. R., et al., “Clinical use of current polygenic risk scores may exacerbate health disparities,” Cell, 2019, https://doi.org/10.1016/j.cell.2019.03.048; National Academies of Sciences, Engineering, and Medicine, “Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups,” 2022, https://doi.org/10.17226/26479; U.S. National Cancer Institute, The Cancer Genome Atlas Program, https://www.cancer.gov/ccg/research/genome-sequencing/tcga.